Our data suggest that pancreatic cancer cells that have the highest density of SAS1B on the cell surface combined with the highest percentage of total cells being SAS1Bpos would be most likely to benefit the greatest from SAS1B targeted ADC therapy. The gene discussed is ASTL; the disease is pancreatic neoplasm.